.RESEARCH STUDY HIGHLIGHT.06 August 2024.
A sizable randomized controlled test along with cisgender women highlights the challenges of adherence to a daily oral preexposure prophylaxis program and also illustrates that twice-yearly shot of lenacapavir can preserve helpful HIV deterrence degrees over 6 months.